3-D Matrix, Ltd. DMTRF

Company Overview

3-D Matrix, Ltd. is a Japan-based biotechnology and medical device company focused on regenerative medicine and surgical hemostasis solutions. The company develops and commercializes synthetic self-assembling peptide technologies used primarily in medical devices and regenerative medicine research, serving hospitals, surgeons, and research institutions. Its flagship commercial product is PuraStat, a synthetic peptide-based hemostatic agent used to control bleeding during surgical and endoscopic procedures, which represents the company’s primary revenue driver.

Founded in 2001 as a university spin-out, the company originated from research conducted by its scientific founder on peptide nanofiber technology. Over time, 3-D Matrix, Ltd. transitioned from a research-centric organization into a commercial-stage company, achieving regulatory approvals in multiple regions and expanding its product applications beyond research use into clinical and surgical settings. The company is publicly listed in Japan and its shares also trade in the U.S. via the OTC market under the ticker DMTRF.